219 related articles for article (PubMed ID: 36729098)
21. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
Ng TL; Liu Y; Dimou A; Patil T; Aisner DL; Dong Z; Jiang T; Su C; Wu C; Ren S; Zhou C; Camidge DR
Cancer; 2019 Apr; 125(7):1038-1049. PubMed ID: 30548240
[TBL] [Abstract][Full Text] [Related]
22. LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA
Tsuboi M; Goldman JW; Wu YL; Johnson ML; Paz-Ares L; Yang JC; Besse B; Su W; Chao BH; Drilon A
Future Oncol; 2022 Sep; 18(28):3133-3141. PubMed ID: 35950566
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic strategies in RET gene rearranged non-small cell lung cancer.
Drusbosky LM; Rodriguez E; Dawar R; Ikpeazu CV
J Hematol Oncol; 2021 Mar; 14(1):50. PubMed ID: 33771190
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of first-line immune checkpoint inhibitors in patients with advanced NSCLC with KRAS, MET, FGFR, RET, BRAF, and HER2 alterations.
Uehara Y; Watanabe K; Hakozaki T; Yomota M; Hosomi Y
Thorac Cancer; 2022 Jun; 13(11):1703-1711. PubMed ID: 35491960
[TBL] [Abstract][Full Text] [Related]
25. Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations.
Subbiah V; Shen T; Terzyan SS; Liu X; Hu X; Patel KP; Hu M; Cabanillas M; Behrang A; Meric-Bernstam F; Vo PTT; Mooers BHM; Wu J
Ann Oncol; 2021 Feb; 32(2):261-268. PubMed ID: 33161056
[TBL] [Abstract][Full Text] [Related]
26. [Chinese expert consensus on the diagnosis and treatment of advanced RET fusion-positive non-small cell lung cancer (2023 edition)].
; ;
Zhonghua Zhong Liu Za Zhi; 2023 Dec; 45(12):991-1002. PubMed ID: 38110308
[TBL] [Abstract][Full Text] [Related]
27. Clinical Outcomes of PD-1/PD-L1 Inhibitors Among Patients With Advanced or Metastatic Non-Small Cell Lung Cancer With BRAF, ERBB2/HER2, MET , or RET Alterations: A Systematic Literature Review.
Akers KG; Oskar S; Zhao B; Frederickson AM; Arunachalam A
J Immunother; 2024 May; 47(4):128-138. PubMed ID: 38112201
[TBL] [Abstract][Full Text] [Related]
28. Predictive molecular pathology in metastatic thyroid cancer: the role of
Nacchio M; Pisapia P; Pepe F; Russo G; Vigliar E; Porcelli T; Luongo C; Iaccarino A; Pagni F; Salvatore D; Troncone G; Malapelle U; Bellevicine C
Expert Rev Endocrinol Metab; 2022 Mar; 17(2):167-178. PubMed ID: 35404189
[TBL] [Abstract][Full Text] [Related]
29. Pralsetinib: chemical and therapeutic development with FDA authorization for the management of RET fusion-positive non-small-cell lung cancers.
Ali F; Neha K; Chauhan G
Arch Pharm Res; 2022 May; 45(5):309-327. PubMed ID: 35598228
[TBL] [Abstract][Full Text] [Related]
30. Exposure-Response Relationships for Pralsetinib in Patients with RET-Altered Thyroid Cancer or RET Fusion-Positive Nonsmall Cell Lung Cancer.
Kassir N; McDougall D; Kuruvilla D; Kim S; Kumar S; Rahman A; Ruf T; Cheeti S; Ankrom W
J Clin Pharmacol; 2024 Jun; 64(6):685-696. PubMed ID: 38337106
[TBL] [Abstract][Full Text] [Related]
31. Selpercatinib for adult patients with locally advanced or metastatic RET-altered solid tumors.
Le D; Konda B
Expert Rev Anticancer Ther; 2023; 23(11):1117-1122. PubMed ID: 37795873
[TBL] [Abstract][Full Text] [Related]
32. Treatment of Advanced Non-Small Cell Lung Cancer with RET Fusions: Reality and Hopes.
Rocco D; Sapio L; Della Gravara L; Naviglio S; Gridelli C
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768754
[TBL] [Abstract][Full Text] [Related]
33. Clinical and Translational Implications of RET Rearrangements in Non-Small Cell Lung Cancer.
Ferrara R; Auger N; Auclin E; Besse B
J Thorac Oncol; 2018 Jan; 13(1):27-45. PubMed ID: 29128428
[TBL] [Abstract][Full Text] [Related]
34. Expert consensus on the diagnosis and treatment of RET gene fusion non-small cell lung cancer in China.
Pu X; Xu C; Wang Q; Wang W; Wu F; Cai X; Song Z; Yu J; Zhong W; Wang Z; Zhang Y; Liu J; Zhang S; Liu A; Li W; Zhan P; Liu H; Lv T; Miao L; Min L; Lin G; Huang L; Yuan J; Jiang Z; Rao C; Lv D; Yu Z; Li X; Tang C; Zhou C; Zhang J; Guo H; Chu Q; Meng R; Liu X; Wu J; Zhou J; Zhu Z; Pan W; Pang F; Huang J; Wang K; Wu F; Shen T; Zou S; Xu B; Wang L; Zhu Y; Lin X; Cai J; Xu L; Li J; Jiao X; Li K; Feng H; Wang L; Du Y; Yao W; Shi X; Niu X; Yuan D; Yao Y; Kang J; Zhang J; Zhang C; Fu J; Huang J; Zhang Y; Sun P; Wang H; Ye M; Wang D; Wang Z; Hao Y; Wang Z; Wan B; Lv D; Lan G; Yang S; Shi L; Wang Y; Li B; Zhang Z; Li Z; Li Y; Liu Z; Yang N; Wang H; Huang W; Hong Z; Wang G; Wang J; Fang M; Fang Y; Zhu X; Shen Y; Zhang Y; Ma S; Song Y; Lu Y; Fang W; Li Z; Wu L
Thorac Cancer; 2023 Nov; 14(31):3166-3177. PubMed ID: 37718634
[TBL] [Abstract][Full Text] [Related]
35. Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial.
Griesinger F; Curigliano G; Thomas M; Subbiah V; Baik CS; Tan DSW; Lee DH; Misch D; Garralda E; Kim DW; van der Wekken AJ; Gainor JF; Paz-Ares L; Liu SV; Kalemkerian GP; Houvras Y; Bowles DW; Mansfield AS; Lin JJ; Smoljanovic V; Rahman A; Kong S; Zalutskaya A; Louie-Gao M; Boral AL; Mazières J
Ann Oncol; 2022 Nov; 33(11):1168-1178. PubMed ID: 35973665
[TBL] [Abstract][Full Text] [Related]
36. Association Between RET Fusions and Efficacy of Pemetrexed-based Chemotherapy for Patients With Advanced NSCLC in China: A Multicenter Retrospective Study.
Shen T; Pu X; Wang L; Yu Z; Li J; Zhang Y; Liang X; Chen H; Xu C; Song Z; Wang W
Clin Lung Cancer; 2020 Sep; 21(5):e349-e354. PubMed ID: 32143967
[TBL] [Abstract][Full Text] [Related]
37. Successful treatment with selpercatinib after pralsetinib-related pneumonitis and intracranial failure in a patient with RET-rearranged nonsmall cell lung cancer.
Cognigni V; Giudice GC; Bozzetti F; Milanese G; Moschini I; Casali M; Mazzaschi G; Tiseo M
Anticancer Drugs; 2024 Jul; 35(6):559-562. PubMed ID: 38453158
[TBL] [Abstract][Full Text] [Related]
38. Pralsetinib-associated pneumonia in RET fusion-positive non-small cell lung cancer.
Gao M; Zhang X; Yan H; Sun D; Yang X; Yuan F; Ju Y; Wang L; Wang J; Zhao W; Zhang D; Li L; Xu X; Ma J; Hu Y; Zhang X
Support Care Cancer; 2023 Nov; 31(12):671. PubMed ID: 37924363
[TBL] [Abstract][Full Text] [Related]
39. Advances in the Diagnosis and Treatment of a Driving Target: RET Rearrangements in non-Small-Cell Lung Cancer (NSCLC) Especially in China.
Li T; Yang WY; Liu TT; Li Y; Liu L; Zheng X; Zhao L; Zhang F; Hu Y
Technol Cancer Res Treat; 2023; 22():15330338221148802. PubMed ID: 36628459
[TBL] [Abstract][Full Text] [Related]
40. Response to immune checkpoint inhibitor combination therapy in metastatic RET-mutated lung cancer from real-world retrospective data.
Yan N; Zhang H; Shen S; Guo S; Li X
BMC Cancer; 2024 Feb; 24(1):178. PubMed ID: 38317126
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
